1-6 of 6
Young-Hyuck Im
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase II DORA Study of Olaparib with or without Durvalumab as a Chemotherapy-Free Maintenance Strategy in Platinum-Pretreated Advanced Triple-Negative Breast Cancer

Open Access
Tira J. Tan, Sarah Sammons, Young-Hyuck Im, Lilin She, Kelly Mundy, Robert Bigelow, Tiffany A. Traina, Carey Anders, Joe Yeong, Ezequiel Renzulli, Sung-Bae Kim, Rebecca Dent
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (7): 1240–1247.
https://doi.org/10.1158/1078-0432.CCR-23-2513
Published: 01 April 2024
View articletitled, Phase II DORA Study of Olaparib with or without Durvalumab as a Chemotherapy-Free Maintenance Strategy in Platinum-Pretreated Advanced Triple-Negative Breast Cancer
Open the PDF for Phase II DORA Study of Olaparib with or without Durvalumab as a Chemotherapy-Free Maintenance Strategy in Platinum-Pretreated Advanced Triple-Negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor–positive/HER2-negative Advanced or Metastatic Breast Cancer

Open Access
David W. Cescon, John Hilton, Serafin Morales Murilo, Rachel M. Layman, Timothy Pluard, Belinda Yeo, In Hae Park, Louise Provencher, Sung-Bae Kim, Young-Hyuck Im, Anastasia Wyce, Anu Shilpa Krishnatry, Kirsty Hicks, Qu Zhang, Olena Barbash, Ahmed Khaled, Thierry Horner, Arindam Dhar, Mafalda Oliveira, Joseph A. Sparano
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (2): 334–343.
https://doi.org/10.1158/1078-0432.CCR-23-0133
Published: 17 January 2024
View articletitled, A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor–positive/HER2-negative Advanced or Metastatic Breast Cancer
Open the PDF for A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor–positive/HER2-negative Advanced or Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2− Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial

Open Access
Yen-Shen Lu, Seock-Ah Im, Marco Colleoni, Fabio Franke, Aditya Bardia, Fatima Cardoso, Nadia Harbeck, Sara Hurvitz, Louis Chow, Joohyuk Sohn, Keun Seok Lee, Saul Campos-Gomez, Rafael Villanueva Vazquez, Kyung Hae Jung, K. Govind Babu, Paul Wheatley-Price, Michelino De Laurentiis, Young-Hyuck Im, Sherko Kuemmel, Nagi El-Saghir, Ruth O'Regan, Claudia Gasch, Nadia Solovieff, Craig Wang, Yongyu Wang, Arunava Chakravartty, Yan Ji, Debu Tripathy
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (5): 851–859.
https://doi.org/10.1158/1078-0432.CCR-21-3032
Published: 01 March 2022
View articletitled, Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2− Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial
Open the PDF for Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2− Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial in another window
Includes: Supplementary data
Journal Articles

Pharmacokinetics, Safety, and Efficacy of Trastuzumab Deruxtecan with Concomitant Ritonavir or Itraconazole in Patients with HER2-Expressing Advanced Solid Tumors

Open Access
Shunji Takahashi, Masato Karayama, Masato Takahashi, Junichiro Watanabe, Hironobu Minami, Noboru Yamamoto, Ichiro Kinoshita, Chia-Chi Lin, Young-Hyuck Im, Issei Achiwa, Emi Kamiyama, Yasuyuki Okuda, Caleb Lee, Yung-Jue Bang
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (21): 5771–5780.
https://doi.org/10.1158/1078-0432.CCR-21-1560
Published: 01 November 2021
View articletitled, Pharmacokinetics, Safety, and Efficacy of Trastuzumab Deruxtecan with Concomitant Ritonavir or Itraconazole in Patients with HER2-Expressing Advanced Solid Tumors
Open the PDF for Pharmacokinetics, Safety, and Efficacy of Trastuzumab Deruxtecan with Concomitant Ritonavir or Itraconazole in Patients with HER2-Expressing Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR+ Advanced Breast Cancer

Available to Purchase
Sara M. Tolaney, Young-Hyuck Im, Emiliano Calvo, Yen-Shen Lu, Erika Hamilton, Andres Forero-Torres, Thomas Bachelot, Michela Maur, Angelica Fasolo, Ralph Tiedt, Lisa Nardi, Uz Stammberger, Ahmed M. Abdelhady, Shiling Ruan, Soo Chin Lee
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (2): 418–428.
https://doi.org/10.1158/1078-0432.CCR-20-0645
Published: 19 January 2021
View articletitled, Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR+ Advanced Breast Cancer
Open the PDF for Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR+ Advanced Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Gefitinib (ZD1839) Monotherapy as a Salvage Regimen for Previously Treated Advanced Non-Small Cell Lung Cancer

Free
Jinny Park, Byung Bae Park, Jee Youn Kim, Se-Hoon Lee, Soon Il Lee, Ho Young Kim, Jung Han Kim, Se Hoon Park, Kyung-Eun Lee, Joon Oh Park, Kihyun Kim, Chul Won Jung, Young Suk Park, Young-Hyuck Im, Won Ki Kang, Mark H. Lee, Keunchil Park
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (13): 4383–4388.
https://doi.org/10.1158/1078-0432.CCR-04-0189
Published: 06 July 2004
View articletitled, Gefitinib (ZD1839) Monotherapy as a Salvage Regimen for Previously Treated Advanced Non-Small Cell Lung Cancer
Open the PDF for Gefitinib (ZD1839) Monotherapy as a Salvage Regimen for Previously Treated Advanced Non-Small Cell Lung Cancer in another window